Prognosis in patients with MDS or AML and bone marrow blasts between 10% and 30% is not associated with blast counts but depends on cytogenetic and molecular genetic characteristics. - Bacher, U.; Kern, W.; Alpermann, T.; Schnittger, S.; Kohlmann, A.; Klein, H.-U.; Dugas, M.; Haferlach, C.; Haferlach, T. (Leukemia (08876924), 2011)